444 related articles for article (PubMed ID: 20382326)
1. Early recognition and prevention of chronic kidney disease.
James MT; Hemmelgarn BR; Tonelli M
Lancet; 2010 Apr; 375(9722):1296-309. PubMed ID: 20382326
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. [New concept of chronic kidney disease and blockade of renin-angiotensin system].
Takeda T; Gejyo F
Nihon Rinsho; 2007 Sep; 65(9):1727-33. PubMed ID: 17877002
[TBL] [Abstract][Full Text] [Related]
4. Renal protection with angiotensin receptor blockers: where do we stand.
Schmieder RE; Ruilope LM; Barnett AH
J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
[TBL] [Abstract][Full Text] [Related]
5. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
6. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
Ratto E; Leoncini G; Viazzi F; Pontremoli R
G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
[TBL] [Abstract][Full Text] [Related]
7. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
Ahmed AK; Kamath NS; El Kossi M; El Nahas AM
Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248
[TBL] [Abstract][Full Text] [Related]
8. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
9. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Barnett A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
[TBL] [Abstract][Full Text] [Related]
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
12. [Antihypertensive treatment for chronic kidney disease].
Kumagai H; Hyodo T; Kushiyama T; Higashi K; Yamamoto K
Nihon Rinsho; 2008 Aug; 66(8):1574-81. PubMed ID: 18700560
[TBL] [Abstract][Full Text] [Related]
13. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
14. The Remission Clinic approach to halt the progression of kidney disease.
;
J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
[TBL] [Abstract][Full Text] [Related]
15. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
16. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
18. [The epidemic of chronic kidney disease requires the estimation of glomerular filtration rate].
Mátyus J; V Oláh A; Ujhelyi L; Kárpáti I; Balla J
Orv Hetil; 2008 Jan; 149(2):77-82. PubMed ID: 18093898
[TBL] [Abstract][Full Text] [Related]
19. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
Ruilope L; Kjeldsen SE; de la Sierra A; Mancia G; Ruggenenti P; Stergiou GS; Bakris GL; Giles TD
Blood Press; 2007; 16(2):72-9. PubMed ID: 17612904
[TBL] [Abstract][Full Text] [Related]
20. Elderly patients with chronic kidney disease: outcomes after 5 years of follow-up.
Heras M; Fernández-Reyes MJ; Sánchez R; Guerrero MT; Molina A; Rodríguez MA; Alvarez-Ude F
Nefrologia; 2012 May; 32(3):300-5. PubMed ID: 22508140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
